The US Food and Drug Administration (FDA) has approved vilazodone tablets (Viibryd, Clinical Data, Inc) for the treatment of major depressive disorder (MDD) in adults.
For the 18 million Americans dealing with daily depression, this is great news!
Vilazodone is the first approved drug that is both a combination selective serotonin reuptake inhibitor (SSRI) and a partial agonist of serotonergic (5HT1A) receptors.
No comments:
Post a Comment